

Supplementary Table 1. Additional Patient Characteristics									
Patient Number	Age at HSCT (years)	Sex	Disease	Conditioning Regimen	Donor	Cell Source	aGVHD	Response to Eculizumab	
1	8.0	F	B-Thalassemia	Busulfan/ Melphalan/ Thiotepa	MUD	Bone Marrow	Yes, stage III	Yes	
2	1.0	F	Hemophagocytic Lymphohistiocytosis	Alemtuzumab/ Fludarabine/ Melphalan	MUD	Bone Marrow	no	Yes	
3	5.0	M	Neuroblastoma	Cyclophosphamide/ Thiotepa; Carboplatin/ Melphalan/ Etoposide	Auto	PBSC	n/a	Yes	
4	10.8	F	Acute Lymphoblastic Leukemia	Cyclophosphamide/ Total Body Irradiation	MUD	Bone Marrow	Yes, stage I	n/a	
5	5.1	F	Hemophagocytic Lymphohistiocytosis	Alemtuzumab/ Fludarabine/ Melphalan	MUD	Bone Marrow	Yes, stage III	Yes	
6	18.0	M	Acute Myeloid Leukemia	Busulfan/ Cyclophosphamide	MUD	Bone Marrow	Yes, stage IV	Yes	
7	8.0	M	Diamond Blackfan Anemia	Busulfan/ Cyclophosphamide	MUD	Bone Marrow	no	n/a	
8	9.6	N	Neuroblastoma	Cyclophosphamide/ Thiotepa; Carboplatin/ Melphalan/ Etoposide	Auto	PBSC	n/a	n/a	
9	1.5	M	Hurler's Syndrome	Alemtuzumab/ Busulfan/ Fludarabine	MUD	Bone Marrow	no	n/a	
10	0.9	F	Hurler's Syndrome	Busulfan/ Fludarabine	MUD	Cord Blood	No	n/a	
11	17.0	M	Atypical Teratoid/ Rhabdoid Tumor	Cisplatin/ Cyclophosphamide/ Vincristine	Auto	PBSC	n/a	n/a	

Note: MUD: Matched Unrelated Donor; Auto: Autologous Transplant; PBSC: Peripheral Blood Stem Cells